Kidney Fibrosis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Kidney Fibrosis – Pipeline Review, H1 2017’, provides an overview of the Kidney Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis

The report reviews pipeline therapeutics for Kidney Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kidney Fibrosis therapeutics and enlists all their major and minor projects

The report assesses Kidney Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kidney Fibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Allergan Plc

Angion Biomedica Corp

Apollo Endosurgery Inc

BiOrion Technologies BV

Cellmid Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

GenKyoTex SA

Horizon Pharma Plc

Intercept Pharmaceuticals Inc

Isarna Therapeutics GmbH

MorphoSys AG

Pharmaxis Ltd

ProMetic Life Sciences Inc

Regulus Therapeutics Inc

Sirnaomics Inc

Symic Biomedical Inc

Vascular Biogenics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Kidney Fibrosis - Overview

Kidney Fibrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Fibrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kidney Fibrosis - Companies Involved in Therapeutics Development

AbbVie Inc

Allergan Plc

Angion Biomedica Corp

Apollo Endosurgery Inc

BiOrion Technologies BV

Cellmid Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

GenKyoTex SA

Horizon Pharma Plc

Intercept Pharmaceuticals Inc

Isarna Therapeutics GmbH

MorphoSys AG

Pharmaxis Ltd

ProMetic Life Sciences Inc

Regulus Therapeutics Inc

Sirnaomics Inc

Symic Biomedical Inc

Vascular Biogenics Ltd

Kidney Fibrosis - Drug Profiles

ANG-3070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3586 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-4021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOT-191 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAB-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cysteamine DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit Galectin-3 for Liver Fibrosis, Pulmonary Fibrosis and Kidney Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Tissue Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GKT-136901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICG-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-0047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lpathomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-4820 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5033A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEW-7197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wnt-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kidney Fibrosis - Dormant Projects

Kidney Fibrosis - Product Development Milestones

Featured News & Press Releases

Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107

Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting

Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis

Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics

Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe

Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015

Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter

Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Kidney Fibrosis – Pipeline by AbbVie Inc, H1 2017

Kidney Fibrosis – Pipeline by Allergan Plc, H1 2017

Kidney Fibrosis – Pipeline by Angion Biomedica Corp, H1 2017

Kidney Fibrosis – Pipeline by Apollo Endosurgery Inc, H1 2017

Kidney Fibrosis – Pipeline by BiOrion Technologies BV, H1 2017

Kidney Fibrosis – Pipeline by Cellmid Ltd, H1 2017

Kidney Fibrosis – Pipeline by Epigen Biosciences Inc, H1 2017

Kidney Fibrosis – Pipeline by Evotec AG, H1 2017

Kidney Fibrosis – Pipeline by Galectin Therapeutics Inc, H1 2017

Kidney Fibrosis – Pipeline by GenKyoTex SA, H1 2017

Kidney Fibrosis – Pipeline by Horizon Pharma Plc, H1 2017

Kidney Fibrosis – Pipeline by Intercept Pharmaceuticals Inc, H1 2017

Kidney Fibrosis – Pipeline by Isarna Therapeutics GmbH, H1 2017

Kidney Fibrosis – Pipeline by MorphoSys AG, H1 2017

Kidney Fibrosis – Pipeline by Pharmaxis Ltd, H1 2017

Kidney Fibrosis – Pipeline by ProMetic Life Sciences Inc, H1 2017

Kidney Fibrosis – Pipeline by Regulus Therapeutics Inc, H1 2017

Kidney Fibrosis – Pipeline by Sirnaomics Inc, H1 2017

Kidney Fibrosis – Pipeline by Symic Biomedical Inc, H1 2017

Kidney Fibrosis – Pipeline by Vascular Biogenics Ltd, H1 2017

Kidney Fibrosis – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Kidney Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports